Education
About Us
Working with TipRanks
Follow Us
Immunome, Inc. (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$23.41
-$0.28(-2.60%)
At close: 4:00 PM EST
$23.41
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.78M
Market Cap
$2.58B
Enterprise Value$1.76B
Total Cash (Recent Filing)$272.64M
Total Debt (Recent Filing)$4.01M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 19, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding110,335,270
10 Day Avg. Volume1,331,355
30 Day Avg. Volume1,781,711
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.44
Price to Sales (P/S)68.88
P/FCF Ratio-3.79
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue182.20
Enterprise Value/Gross Profit-43.83
Enterprise Value/Ebitda-8.75
Forecast
1Y Price Target
$34.73Price Target Upside48.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.5
Revenue Forecast (FY)$9.98M
Bulls Say, Bears Say
Bulls Say
Financial Runway And Commercial ReadinessA recent $400 million equity financing strengthens the balance sheet to support a potential commercial launch of varegacestat and continued pipeline development, with updated cash runway guidance extending into 2028 to lower near-term financing risk.
Pipeline Advancement And Novel TechnologyUpcoming milestones, including first Phase 1 data for the ROR1-ADC IM-1021 and the planned initiation of IM-3050 in 2026, could validate the company's next-generation antibody-drug conjugate approach and broaden addressable indications.
Regulatory And Clinical MilestonePositive Phase 3 results for varegacestat underpin a planned New Drug Application submission, positioning the therapy as a potential best-in-class systemic option for desmoid tumors and creating a clear regulatory pathway to commercial approval.
Bears Say
Clinical Outcome UncertaintyKey clinical readouts for important programs remain pending, creating uncertainty about trial outcomes and the timing of potential approvals or commercial success.
Market Sentiment And Short InterestRelatively high short interest, at around twenty percent of the float, indicates market skepticism that could amplify downside pressure if negative news or execution issues arise.
Immunome News
IMNM FAQ
What was Immunome, Inc.’s price range in the past 12 months?
Immunome, Inc. lowest stock price was $5.15 and its highest was $27.65 in the past 12 months.
What is Immunome, Inc.’s market cap?
Immunome, Inc.’s market cap is $2.58B.
When is Immunome, Inc.’s upcoming earnings report date?
Immunome, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 33 days.
How were Immunome, Inc.’s earnings last quarter?
Immunome, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.084.
Is Immunome, Inc. overvalued?
According to Wall Street analysts Immunome, Inc.’s price is currently Undervalued.
Does Immunome, Inc. pay dividends?
Immunome, Inc. does not currently pay dividends.
What is Immunome, Inc.’s EPS estimate?
Immunome, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Immunome, Inc. have?
Immunome, Inc. has 110,335,270 shares outstanding.
What happened to Immunome, Inc.’s price movement after its last earnings report?
Immunome, Inc. reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -1.677%.
Which hedge fund is a major shareholder of Immunome, Inc.?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.73 (48.36% Upside)
$34.73 (48.36% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 223.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.94%
12-Months-Change
Fundamentals
Return on Equity
-93.04%
Trailing 12-Months
Asset Growth
16.54%
Trailing 12-Months
Company Description
Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$34.73
▲(48.36% Upside)
Technical Analysis
Ownership Overview
4.91% Insiders
21.74% Mutual Funds
0.04% Other Institutional Investors
62.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---